These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 16233888)

  • 41. Boron neutron capture therapy for glioblastoma.
    Yamamoto T; Nakai K; Matsumura A
    Cancer Lett; 2008 Apr; 262(2):143-52. PubMed ID: 18313207
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantitative bioimaging of p-boronophenylalanine in thin liver tissue sections as a tool for treatment planning in boron neutron capture therapy.
    Reifschneider O; Schütz CL; Brochhausen C; Hampel G; Ross T; Sperling M; Karst U
    Anal Bioanal Chem; 2015 Mar; 407(9):2365-71. PubMed ID: 25015045
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II.
    Imahori Y; Ueda S; Ohmori Y; Sakae K; Kusuki T; Kobayashi T; Takagaki M; Ono K; Ido T; Fujii R
    Clin Cancer Res; 1998 Aug; 4(8):1833-41. PubMed ID: 9717809
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of intra-arterial administration of boron compounds on dose-volume histograms in boron neutron capture therapy for recurrent head-and-neck tumors.
    Suzuki M; Sakurai Y; Nagata K; Kinashi Y; Masunaga S; Ono K; Maruhashi A; Kato I; Fuwa N; Hiratsuka J; Imahori Y
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1523-7. PubMed ID: 17056200
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Survival benefit of boron neutron capture therapy for recurrent malignant gliomas.
    Miyatake S; Kawabata S; Yokoyama K; Kuroiwa T; Michiue H; Sakurai Y; Kumada H; Suzuki M; Maruhashi A; Kirihata M; Onoc K
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S22-4. PubMed ID: 19394240
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Suitability of boron carriers for BNCT: accumulation of boron in malignant and normal liver cells after treatment with BPA, BSH and BA.
    Chou FI; Chung HP; Liu HM; Chi CW; Lui WY
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S105-8. PubMed ID: 19375330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. L-DOPA preloading increases the uptake of borophenylalanine in C6 glioma rat model: a new strategy to improve BNCT efficacy.
    Capuani S; Gili T; Bozzali M; Russo S; Porcari P; Cametti C; D'Amore E; Colasanti M; Venturini G; Maraviglia B; Lazzarino G; Pastore FS
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):562-7. PubMed ID: 18793958
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Boronophenylalanine uptake in C6 glioma model is dramatically increased by L-DOPA preloading.
    Capuani S; Gili T; Bozzali M; Russo S; Porcari P; Cametti C; Muolo M; D'Amore E; Maraviglia B; Lazzarino G; Pastore FS
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S34-6. PubMed ID: 19375337
    [TBL] [Abstract][Full Text] [Related]  

  • 49. L-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors.
    Detta A; Cruickshank GS
    Cancer Res; 2009 Mar; 69(5):2126-32. PubMed ID: 19244126
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of boron distribution in vivo for boron neutron capture therapy using two different boron compounds by secondary ion mass spectrometry.
    Yokoyama K; Miyatake S; Kajimoto Y; Kawabata S; Doi A; Yoshida T; Okabe M; Kirihata M; Ono K; Kuroiwa T
    Radiat Res; 2007 Jan; 167(1):102-9. PubMed ID: 17214510
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients.
    Kawabata S; Miyatake S; Nonoguchi N; Hiramatsu R; Iida K; Miyata S; Yokoyama K; Doi A; Kuroda Y; Kuroiwa T; Michiue H; Kumada H; Kirihata M; Imahori Y; Maruhashi A; Sakurai Y; Suzuki M; Masunaga S; Ono K
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S15-8. PubMed ID: 19398348
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Boron neutron capture therapy applied to undifferentiated thyroid carcinoma].
    Pisarev MA; Dagrosa MA; Thomasz L; Juvenal G
    Medicina (B Aires); 2006; 66(6):569-73. PubMed ID: 17240633
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Homogeneous boron targeting of heterogeneous tumors for boron neutron capture therapy (BNCT): chemical analyses in the hamster cheek pouch oral cancer model.
    Heber EM; Trivillin VA; Nigg DW; Itoiz ME; Gonzalez BN; Rebagliati RJ; Batistoni D; Kreimann EL; Schwint AE
    Arch Oral Biol; 2006 Oct; 51(10):922-9. PubMed ID: 16696934
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Boron neutron capture therapy using mixed epithermal and thermal neutron beams in patients with malignant glioma-correlation between radiation dose and radiation injury and clinical outcome.
    Kageji T; Nagahiro S; Matsuzaki K; Mizobuchi Y; Toi H; Nakagawa Y; Kumada H
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1446-55. PubMed ID: 16750328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of boron concentrations in blood from patients on boron neutron capture therapy.
    Shibata Y; Matsumura A; Yamamoto T; Akutsu H; Yasuda S; Nakai K; Nose T; Yamamoto K; Kumada H; Hori N; Ohtake S
    Anticancer Res; 2003; 23(6D):5231-5. PubMed ID: 14981995
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-survivors of glioblatoma treated with boron neutron capture therapy (BNCT).
    Kageji T; Mizobuchi Y; Nagahiro S; Nakagawa Y; Kumada H
    Appl Radiat Isot; 2011 Dec; 69(12):1800-2. PubMed ID: 21463946
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 1H and 10B NMR and MRI investigation of boron- and gadolinium-boron compounds in boron neutron capture therapy.
    Bonora M; Corti M; Borsa F; Bortolussi S; Protti N; Santoro D; Stella S; Altieri S; Zonta C; Clerici AM; Cansolino L; Ferrari C; Dionigi P; Porta A; Zanoni G; Vidari G
    Appl Radiat Isot; 2011 Dec; 69(12):1702-5. PubMed ID: 21371896
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Noninvasive quantitative in vivo mapping and metabolism of boronophenylalanine (BPA) by nuclear magnetic resonance (NMR) spectroscopy and imaging.
    Bendel P; Margalit R; Koudinova N; Salomon Y
    Radiat Res; 2005 Nov; 164(5):680-7. PubMed ID: 16238447
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimization of boron neutron capture therapy for the treatment of undifferentiated thyroid cancer.
    Dagrosa MA; Thomasz L; Longhino J; Perona M; Calzetta O; Blaumann H; Rebagliati RJ; Cabrini R; Kahl S; Juvenal GJ; Pisarev MA
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1059-66. PubMed ID: 17967301
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Determination of boron-containing compounds in urine and blood plasma from boron neutron capture therapy patients. The importance of using coupled techniques.
    Svantesson E; Capala J; Markides KE; Pettersson J
    Anal Chem; 2002 Oct; 74(20):5358-63. PubMed ID: 12403593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.